Your browser doesn't support javascript.
loading
Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study.
Nagata, Naoyoshi; Nishijima, Suguru; Kojima, Yasushi; Hisada, Yuya; Imbe, Koh; Miyoshi-Akiyama, Tohru; Suda, Wataru; Kimura, Moto; Aoki, Ryo; Sekine, Katsunori; Ohsugi, Mitsuru; Miki, Kuniko; Osawa, Tsuyoshi; Ueki, Kohjiro; Oka, Shinichi; Mizokami, Masashi; Kartal, Ece; Schmidt, Thomas S B; Molina-Montes, Esther; Estudillo, Lidia; Malats, Nuria; Trebicka, Jonel; Kersting, Stephan; Langheinrich, Melanie; Bork, Peer; Uemura, Naomi; Itoi, Takao; Kawai, Takashi.
Afiliação
  • Nagata N; Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: nnagata_ncgm@yahoo.co.jp.
  • Nishijima S; Computational Bio-Big Data Open Innovation Lab, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan; Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heid
  • Kojima Y; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Hisada Y; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Imbe K; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Miyoshi-Akiyama T; Pathogenic Microbe Laboratory, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Suda W; Laboratory for Microbiome Sciences, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
  • Kimura M; Department of Clinical Research Strategic Planning Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Aoki R; Institute of Health Sciences, Ezaki Glico Co., Ltd., Osaka, Japan.
  • Sekine K; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Tokyo, Japan.
  • Ohsugi M; Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Miki K; Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Osawa T; Division of Nutriomics and Oncology, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
  • Ueki K; Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Oka S; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Mizokami M; Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, Chiba, Japan.
  • Kartal E; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
  • Schmidt TSB; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
  • Molina-Montes E; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain.
  • Estudillo L; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain.
  • Malats N; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain.
  • Trebicka J; Section for Translational Hepatology, Department of Internal Medicine I, Goehte University Frankfurt, Frankfurt, Germany; European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
  • Kersting S; Department of Surgery, University Hospital of Erlangen, Erlangen, Germany; Department of Surgery, University Clinic Greifswald, Greifswald, Germany.
  • Langheinrich M; Department of Surgery, University Hospital of Erlangen, Erlangen, Germany; Department of Surgery, University Clinic Greifswald, Greifswald, Germany.
  • Bork P; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany; Department of Bioinformatics, Biocenter, University of Würzburg, Würzburg, Germany.
  • Uemura N; Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Tokyo, Japan.
  • Itoi T; Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
  • Kawai T; Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan.
Gastroenterology ; 163(1): 222-238, 2022 07.
Article em En | MEDLINE | ID: mdl-35398347
BACKGROUND & AIMS: To identify gut and oral metagenomic signatures that accurately predict pancreatic ductal carcinoma (PDAC) and to validate these signatures in independent cohorts. METHODS: We conducted a multinational study and performed shotgun metagenomic analysis of fecal and salivary samples collected from patients with treatment-naïve PDAC and non-PDAC controls in Japan, Spain, and Germany. Taxonomic and functional profiles of the microbiomes were characterized, and metagenomic classifiers to predict PDAC were constructed and validated in external datasets. RESULTS: Comparative metagenomics revealed dysbiosis of both the gut and oral microbiomes and identified 30 gut and 18 oral species significantly associated with PDAC in the Japanese cohort. These microbial signatures achieved high area under the curve values of 0.78 to 0.82. The prediction model trained on the Japanese gut microbiome also had high predictive ability in Spanish and German cohorts, with respective area under the curve values of 0.74 and 0.83, validating its high confidence and versatility for PDAC prediction. Significant enrichments of Streptococcus and Veillonella spp and a depletion of Faecalibacterium prausnitzii were common gut signatures for PDAC in all the 3 cohorts. Prospective follow-up data revealed that patients with certain gut and oral microbial species were at higher risk of PDAC-related mortality. Finally, 58 bacteriophages that could infect microbial species consistently enriched in patients with PDAC across the 3 countries were identified. CONCLUSIONS: Metagenomics targeting the gut and oral microbiomes can provide a powerful source of biomarkers for identifying individuals with PDAC and their prognoses. The identification of shared gut microbial signatures for PDAC in Asian and European cohorts indicates the presence of robust and global gut microbial biomarkers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Metagenômica Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Gastroenterology Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Metagenômica Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Gastroenterology Ano de publicação: 2022 Tipo de documento: Article